News for NeoGenomics, Inc. (NEO.MX)

NeoGenomics Inc (NEO), a prominent oncology testing services company, has announced its participation in several upcoming investor conferences. The company will

NeoGenomics, Inc. (”œNeoGenomics” or the ”œCompany”) (NASDAQ:NEO), a leading oncology testing services company, today announced the Company will particip

Operator: Welcome to the NeoGenomics Fourth Quarter and Full Year 2024 Financial Results Conference Call and Webcast. At this time, all participants are in a listen-only mode.

NeoGenomics Inc (NEO), a leading oncology testing services company, announced its financial results for the fourth quarter and full year ending December 31, 202

Revenue: $172 million for Q4, marking the ninth consecutive quarter of double-digit growth.Clinical Testing Volumes: Increased by 9% year-over-year.Revenue per

NeoGenomics (NEO) shares experienced a significant drop of 24.13% following the release of its earnings report, which revealed that the company's revenue failed

The following slide deck was published by NeoGenomics, Inc.

NeoGenomics, Inc. (Nasdaq: NEO) (the ”œCompany”), a leading oncology testing services company, today announced its fourth-quarter and full year results for

On December 31, 2024, JANUS HENDERSON GROUP PLC (Trades, Portfolio) made a strategic decision to reduce its holdings in NeoGenomics Inc (NEO) by 438,117 shares.

Shares of NeoGenomics Inc (NEO) surged 4.60% in mid-day trading on Feb 14. The stock reached an intraday high of $14.73, before settling at $14.55, up from

**media[528155]**

Shares of NeoGenomics Inc (NEO) fell 3.33% in mid-day trading on Jan 16. The stock reached an intraday low of $14.00, before recovering slightly to $14.22,

NeoGenomics Inc (NEO), a prominent oncology testing services company, has released its financial guidance for fiscal year 2025, along with an update to its Long

NeoGenomics, Inc. (”œNeoGenomics” or the ”œCompany”) (NASDAQ:NEO),a leading oncology testing services company, today provided financial guidance for fisc

NeoGenomics Inc (NEO), a leading oncology testing services company, announced that Chris Smith will retire as Chief Executive Officer and board member effective

NeoGenomics, Inc. (”œNeoGenomics” or the ”œCompany”) (NASDAQ:NEO), a leading oncology testing services company, today announced that Chris Smith will ret

Summary NeoGenomics Inc (NEO), a prominent player in oncology testing services, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Confer

NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, will attend the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, C

NeoGenomics Inc (NEO), a leader in oncology testing services, announced the publication of a groundbreaking study in ESMO Open. The study demonstrates the poten